[1]
Jones AG, McDonald TJ, Shields BM. Markers of β-cell failure predict poor glycemic response to glp-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 2016; 39: 250-7.
[2]
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018; 41(Suppl. 1): S13-27.
[3]
Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: A disease with increasing heterogeneity. Lance 2014; 383(9922): 1084-94.
[4]
Gale EA. Latent autoimmune diabetes in adults: A guide for the perplexed. Diabetologia 2005; 48: 2195-9.
[5]
Bloomgarden Z. Is insulin the preferred treatment for HbA1c >9%? J Diabetes 2017; 9: 814-6.
[6]
Brophy S, Yderstraede K, Mauricio D, et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008; 31: 439-41.
[7]
Wod M, Yderstræde KB, Halekoh U, Beck-Nielsen H, Højlund K. Metabolic risk profiles in diabetes stratified according to age at onset, islet autoimmunity and fasting C-peptide. Diabetes Res Clin Pract 2017; 134: 62-71.
[8]
Rolandsson O, Palmer JP. Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 2010; 53: 1250-3.
[9]
Lohmann T, Nietzschmann U, Kiess W. “Lady-like”: is there a latent autoimmune diabetes in the young? Diabetes Care 2000; 23: 1707-8.
[10]
Thunander M, Petersson C, Jonzon K, Fornander J, Ossiansson B, Torn C. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 2008; 82: 247-55.
[11]
Sørgjerd EP, Skorpen F, Kvaløy K, Midthjell K, Grill V. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway. Diabetologia 2012; 55: 1310-8.
[12]
Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999; 48: 983-8.
[13]
Radenkovic M, Silver C, Arvastsson J, et al. Altered regulatory T cell phenotype in latent autoimmune diabetes of the adults (LADA). Clin Exp Immunol 2016; 186: 46-56.
[14]
Brooks-Worrell BM, Reichow JL, Goel A, Ismail H. Palmer Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 2011; 34: 168-73.
[15]
Al-Majdoub M, Ali A, Storm P, Rosengren AH, Groop L, Spégel P. Metabolite Profiling of LADA Challenges the View of a Metabolically Distinct Subtype. Diabetes 2017; 66: 806-14.
[16]
Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350(9087): 1288-93.
[17]
Desai M, Cull CA, Horton VA, et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 2007; 50: 2052-60.
[18]
Hillman M, Törn C, Landin-Olsson M. DISS study group The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3 years after clinical onset. Clin Exp Immunol 2009; 157: 255-60.
[19]
Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001; 44: 3-15.
[20]
Lindholm E, Hallengren B, Agardh CD. Gender differences in GAD antibody-positive diabetes mellitus in relation to age at onset, C-peptide and other endocrine autoimmune diseases. Diabetes Metab Res Rev 2004; 20: 158-64.
[21]
Hawa MI, Kolb H, Schloot N, et al. Action LADA consortium Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013; 36: 908-13.
[23]
Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: Current knowledge and implications for management. Nat Rev Endocrinol 2017; 13: 674-86.
[24]
Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015; 58: 980-7.
[25]
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-10.
[26]
Brooks-Worrell BM, Palmer JP. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 2013; 171: 164-70.
[27]
Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: A cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2018; 6(2): 122-9.
[28]
Buzzetti R, Di Pietro S, Giaccari A, et al. Non Insulin Requiring Autoimmune Diabetes Study Group High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007; 30: 932-8.
[29]
Radtke MA, Midthjell K, Nilsen TI, Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: Results from the Nord-Trøndelag Health (HUNT) study. Diabetes Care 2009; 32: 245-50.
[30]
Carlsson S, Midthjell K, Tesfamarian MY, Grill V. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trøndelag health study. Diabetologia 2007; 50: 55-8.
[31]
Wilkin TJ. Is autoimmunity or insulin resistance the primary driver of type 1 diabetes? Curr Diab Rep 2013; 13: 651-6.